# PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects

> **NCT02807077** · PHASE1 · COMPLETED · sponsor: **CTI BioPharma** · enrollment: 40 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Pacritinib

## Key facts

- **NCT ID:** NCT02807077
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02807077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02807077, "PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02807077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*